| Pre-LVAD (n = 22) | HT Patient (n = 7) | P Value* | Post-LVAD (n = 6) | P Value†|
---|---|---|---|---|---|
Age, years | 58 (48–64) | 55 (46–62) | 0.459 | 44 (41–51) | 0.031 |
Male gender, n (%) | 19 (86) | 5 (71) | 0.569 | 6 (100) | 1.000 |
Etiology, n (%) | - | - | 0.202 | - | 0.673 |
IDC | 12 (55) | 6 (86) | Â | 45 (67) | Â |
IHD | 10 (46) | 1 (14) | Â | 2 (33) | Â |
Treatments, n (%) | - | - | Â | - | Â |
ACE-I and/or ARB | 13 (59) | 5 (71) | 0.677 | 4 (67) | 1.000 |
Beta-blockers | 16 (80) | 5 (71) | 0.633 | 4 (67) | 0.596 |
Statins | 6 (27) | 2 (29) | 1.000 | - | 0.284 |
Antiplatelet agents | 12 (54) | 2 (29) | 0.390 | 6 (100)§ | 0.062 |
Inotropic support | 11 (50) | 1 (14) | 0.187 | 2 (33) | 0.655 |
Creatinine, mg/dL | 1.08 (0.9-1.53) | 1.32 (1.00-1.78) | 0.313 | 0.95 (0.83-1.48) | 0.599 |
t-Bil, mg/dL | 1.43 (0.55-1.90) | 0.76 (0.48-1.14) | 0.212 | 0.79 (0.62-1.35) | 0.199 |
NT-proBNP, ng/L | 2838 (1371–6042) | 2389 (840–5762) | 0.522 | 599 (158–1036) | 0.007 |
LVEF, % | 23 (19–25) | 28 (20–29) | 0.220 | 32 (20–33) | 0.104 |
LVEDV, mL | 202 (173–291) | 228 (206–300) | 0.185 | 237 (178–260) | 0.820 |
LVEDD, mm | 67 (57–71) | 70 (68–79) | 0.132 | 68 (60–75) | 0.633 |
RAP, mmHg | 5 (3–10) | 3 (2–5) | 0.074 | 3 (2–6) | 0.969 |
PCWP, mmHg | 25 (17–31) | 11 (4–20) | 0.019 | 10 (3–13) | 0.023 |
CI, L/min/m 2 | 1.7 (1.4-2.2) | 2.0 (1.5-2.7) | 0.362 | 3.0 (2.2-3.3) | 0.085 |
PAPs, mmHg | 55 (42–63) | 28 (19–42) | 0.012 | 29 (21–33) | 0.006 |